Pfizer Could Seek OK For COVID-19 Vaccine By October

PEARL RIVER, NY — Pfizer and BioNTech are on track to seek regulatory review of their mRNA-based vaccine program, BNT162b2, as early as October 2020.

If regulatory authorization or approval is obtained, the companies plan to supply up to 100 million doses worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021, Pfizer officials said.

The companies released new data yesterday that helped inform Pfizer and BioNTech’s decision to select BNT162b2 as the lead candidate to advance into pivotal trials.

"We are proud to share our findings with the scientific community as we continue our work to deliver a safe and effective vaccine to combat this devastating virus," Pearl River, N.Y.-based Kathrin Jansen, senior vice president and head of Vaccine Research & Development at Pfizer Inc. told Patch. "We are especially pleased to offer these early data showing our vaccine candidate’s promising safety and immunogenicity profile from the U.S. trial and we look forward to sharing T cell immune response data from the German trial in the near future."